Medivation (NASDAQ:MDVN) has tumbled 1.13% during the past week and has dropped 2.03% in the last 4 week period. The company has outperformed the S&P 500 by 0.05% in the past week but underperformed the index by 2.93% in the last 4 weeks.
Medivation (NASDAQ:MDVN): The stock opened at $59.00 on Friday but the bulls could not build on the opening and the stock topped out at $59.64 for the day. The stock traded down to $58.50 during the day, due to lack of any buying support eventually closed down at $59.33 with a loss of -0.05% for the day. The stock had closed at $59.36 on the previous day. The total traded volume was 2,914,099 shares.
The company shares have rallied 0.29% from its 1 Year high price. On May 10, 2016, the shares registered one year high at $62.94 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $60.29 and the 200 Day Moving Average price is recorded at $45.55.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Powell Andrew Kenneth William, officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., had unloaded 2,578 shares at an average price of $60.42 in a transaction dated on June 6, 2016. The total value of the transaction was worth $155,763.
Many analysts have stated their opinion on the company shares. Brokerage firm Citigroup upgrades its rating on Medivation (NASDAQ:MDVN). As per the latest information, the brokerage house raises the price target to $73 per share from a prior target of $37. The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by the firm was issued on May 6, 2016. Currently the company Insiders own 4% of Medivation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.41% . Institutional Investors own 90.82% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of 0.7%.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.